Shine Justice (ASX:SHJ) has given investors a result with two very different readings.
On the surface, the first half of FY26 looked like a clear recovery. Revenue rose. EBITDA lifted sharply. Net profit returned after a loss in the prior corresponding period. The personal injury practice did most of the heavy lifting.
Then the cash flow line arrived.
That is the useful tension in the Shine Justice result. The legal work appears to be improving, but the timing of cash receipts, especially in class actions, still matters more than a clean headline profit number.
The profit line finally stopped fighting the story
Shine Justice reported first-half revenue and other income of A$108.8 million for the six months to 31 December 2025, up 8% from A$100.7 million a year earlier. EBITDA rose 77% to A$21.1 million, while adjusted EBITDA increased 30% from A$16.2 million to A$21.1 million. NPAT came in at A$6.7 million, compared with a A$1.7 million loss in the prior corresponding period.
That is not a small repair job. It suggests the business has moved past the messier FY25 period, when statutory revenue rose but adjusted EBITDA fell and a A$9.6 million write-down hit the reported result. Shine’s FY25 result also included A$204.4 million of statutory revenue, A$38.4 million of adjusted EBITDA and A$30.6 million of gross operating cash flow.
The cleaner first-half profit matters because Shine is not a conventional services business. Its accounting depends heavily on work in progress, case progression, court approvals and settlement timing. A return to profit is useful. It is not the whole answer.
Personal injury is doing the quiet work
The personal injury division is the steadier part of the business, and in the first half it looked like the engine room again.
Personal injury revenue rose to A$90.6 million from A$82.0 million, while segment EBITDA increased to A$20.3 million from A$13.8 million. Shine said the improvement came from increased legal work, better billing recovery and fewer fee write-offs.
That is the constructive part of the result. It points to operational improvement rather than a one-off accounting lift. A legal services company can talk about strategy all it likes, but for Shine the test is usually simpler: more legal work, better recovery, fewer write-offs.
A$20.3 million of personal injury EBITDA in six months.
That single number carries more weight than most of the presentation language around it.
Class actions remain the swing factor
The class actions division is where the result gets less tidy.
Class actions revenue was broadly flat at A$17.9 million, compared with A$17.7 million a year earlier. Segment EBITDA fell to A$1.2 million from A$2.3 million. Shine also recorded a A$2.3 million write-down tied to lower than expected recoverability on a legacy self-funded class action.
That does not make the class actions business unattractive by default. It does mean investors need to treat the division as a timing-sensitive, funding-sensitive and court-cycle-sensitive contributor, not a smooth annuity.
There is potential there. Shine said four in-principle class action settlement agreements were reached during the half, with further settlements expected in the second half. The catch is that funds are received only after settlement deeds are agreed and costs are approved by the court.
The filing is not saying the money disappeared. It is saying the money did not arrive when the half-year cash flow needed it.
The cash flow line is the uncomfortable part
Gross operating cash flow was negative A$6.3 million, down from positive A$4.1 million in the prior corresponding period. Net cash outflow from operating activities was A$12.9 million, compared with a A$1.8 million outflow a year earlier.
Shine said both measures were affected by A$17.6 million of expected class action receipts that were delayed by case resolution and court approval cycles. A$8.5 million of those receipts arrived in January and February 2026, with the remainder expected before the end of the third quarter.
That explanation is important, but it does not erase the pressure. Cash and cash equivalents fell from A$18.1 million at 30 June 2025 to A$1.1 million at 31 December 2025. Net debt rose to A$79.9 million, from A$53.6 million at 30 June 2025.
This is the real investor question: does Shine’s cash flow normalise as delayed receipts land, or does the class actions model keep creating lumpy half-year surprises?
The management change puts the US plan in sharper focus
There is also a leadership angle. On 15 April 2026, Shine said Simon Morrison would move from Managing Director to Executive Director to focus on the group’s international growth agenda, including its International Mass Torts program. Carolyn Barker AM, appointed Group CEO in February 2025, continues to lead the broader group.
That split is interesting. It suggests Shine wants dedicated senior attention on the international opportunity, while keeping the core business under a CEO structure that was reset in FY25. The opportunity is clear enough: mass torts and class actions can be large, high-profile and valuable when they work.
The risk is just as clear. International expansion can absorb management time and capital before the benefits show up cleanly in earnings or cash.
What would make the recovery feel cleaner
The next result does not need a flashy story. It needs proof that the first-half profit improvement can turn into cash.
Investors may be watching for three things: receipt of the delayed class action funds, further improvement in personal injury billing recovery, and evidence that international mass torts are being funded and advanced without stretching the balance sheet. The interim dividend also matters, with Shine recommending a fully franked 1.5 cents per share dividend payable on 24 April 2026.
Shine’s first-half result was better than the loss-making comparison period. The harder question is whether the cash flow catches up with the profit before debt becomes the louder part of the story.
